Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

NCT04998812 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04998812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
April 13, 2022
Completion date
July 14, 2025
Enrollment
70 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

clinically isolated syndrome, multiple sclerosis